In contrast, other OTU members exert anti-cancer effects in specific cancers, such as YOD1 in HNSCC (71) and cervical cancer (72); OTUD1 and OTUD6B in clear cell renal cell carcinoma (ccRCC) (73, 74); TNFAIP3 in nasopharyngeal carcinoma (NPC) (75). This evidence concerns the gene YOD1 and nasopharyngeal carcinoma.